Summary
ancreatic cancer is the 12th most common cancer globally, and the fourth most fatal, with a mortality rate of 10.9 deaths per 100,000 people per year. The poor prognosis of pancreatic cancer patients has highlighted a significant need for new and improved approaches to treatment, which is not being met by the current market.A highly active pancreatic cancer pipeline contains an array of products with varying molecule types and mechanisms of action, which provides a striking contrast to the current, chemotherapy dominated, market.
Scope
- Gemcitabine based regimens continue to dominate the market, which has seen few new entrants over the past decade. The continued reliance on generic chemotherapies is one reason why the prognosis has shown little improvement.
- What survival benefits do current therapies provide?
- What are the current unmet needs that the pipeline needs to address?
- The pipeline contains a plethora of molecule types and molecular targets not present on the market, including a large focus on therapies targeting common oncogenic pathways and signaling intermediates such as PI3K/Akt.
Reasons to buy
- Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
- Visualize the composition of the pancreatic cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Analyze the pancreatic cancer pipeline, and stratify by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches the treating pancreatic cancer.
Browse full report @ http://www.aarkstore.com/pharmaceuticals-healthcare/127902/frontier-pharma-pancreatic-cancer-identifying-and-commercializing-first-in-class-innovation
Table of Content :
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 4
2.1 Large and Diverse Pipeline Contrasts the Limited Market 4
2.2 Pancreatic Cancer Shows High Levels of First-in-Class Innovation 4
2.3 High Deal Activity Reflects Dynamic Pipeline 4
3 The Case for Innovation 5
3.1 Growing Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Developments Remain Attractive 6
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 7
List Of Tables
Table 1: Tumor Node Metastasis Classification 13
Table 2: Pancreatic Cancer Therapeutics, ECOG Performance Status Scores and Description 15
Table 3: Pancreatic Cancer Therapeutics, Common Endpoints in Oncology Clinical Trials and their Description 16
Table 4: Pancreatic Cancer Therapeutics, Efficacy of Gemcitabine Monotherapy 16
Table 5: Pancreatic Cancer Therapeutics, Efficacy of Gemcitabine Monotherapy 17
Table 6: Pancreatic Cancer Therapeutics, Efficacy of Gemcitabine in Combination with Eloxatin 20
About Aarkstore Enterprise
Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.
Best Selling Reports :
JCR Pharmaceuticals Co., Ltd. (4552) - Financial and Strategic SWOT Analysis Review
Taro Pharmaceutical Industries Ltd. (TARO) - Financial and Strategic SWOT Analysis Review
Laboratoires Pierre Fabre SA - Strategic SWOT Analysis Review
ancreatic cancer is the 12th most common cancer globally, and the fourth most fatal, with a mortality rate of 10.9 deaths per 100,000 people per year. The poor prognosis of pancreatic cancer patients has highlighted a significant need for new and improved approaches to treatment, which is not being met by the current market.A highly active pancreatic cancer pipeline contains an array of products with varying molecule types and mechanisms of action, which provides a striking contrast to the current, chemotherapy dominated, market.
- Gemcitabine based regimens continue to dominate the market, which has seen few new entrants over the past decade. The continued reliance on generic chemotherapies is one reason why the prognosis has shown little improvement.
- What survival benefits do current therapies provide?
- What are the current unmet needs that the pipeline needs to address?
- The pipeline contains a plethora of molecule types and molecular targets not present on the market, including a large focus on therapies targeting common oncogenic pathways and signaling intermediates such as PI3K/Akt.
Reasons to buy
- Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the available treatment options available at each stage of diagnosis.
- Visualize the composition of the pancreatic cancer market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Analyze the pancreatic cancer pipeline, and stratify by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches the treating pancreatic cancer.
Browse full report @ http://www.aarkstore.com/pharmaceuticals-healthcare/127902/frontier-pharma-pancreatic-cancer-identifying-and-commercializing-first-in-class-innovation
Table of Content :
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 4
2.1 Large and Diverse Pipeline Contrasts the Limited Market 4
2.2 Pancreatic Cancer Shows High Levels of First-in-Class Innovation 4
2.3 High Deal Activity Reflects Dynamic Pipeline 4
3 The Case for Innovation 5
3.1 Growing Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Developments Remain Attractive 6
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 7
List Of Tables
Table 1: Tumor Node Metastasis Classification 13
Table 2: Pancreatic Cancer Therapeutics, ECOG Performance Status Scores and Description 15
Table 3: Pancreatic Cancer Therapeutics, Common Endpoints in Oncology Clinical Trials and their Description 16
Table 4: Pancreatic Cancer Therapeutics, Efficacy of Gemcitabine Monotherapy 16
Table 5: Pancreatic Cancer Therapeutics, Efficacy of Gemcitabine Monotherapy 17
Table 6: Pancreatic Cancer Therapeutics, Efficacy of Gemcitabine in Combination with Eloxatin 20
About Aarkstore Enterprise
Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.
Best Selling Reports :
JCR Pharmaceuticals Co., Ltd. (4552) - Financial and Strategic SWOT Analysis Review
Taro Pharmaceutical Industries Ltd. (TARO) - Financial and Strategic SWOT Analysis Review
Laboratoires Pierre Fabre SA - Strategic SWOT Analysis Review
